^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners

TEST:
Immunoprint®

Company:
NeraCare
Type:
Laboratory Developed Test
Related tests:

Details

Evidence
The immunoprint test provides a genomic-based, comprehensive, individualized risk assessment for stage I-II melanoma patients. The test uses immunohistochemistry (IHC) to measure the expression of seven proteins - comprising of five risk markers (Bax, Bcl-X, COX-2, PTEN and presence of CD20-positive B-lymphocytes) and two ‘protective’ markers (loss of MTAP and loss of ß-catenin) in a tumor sample after it has been removed by surgery or biopsy.
Cancer:
Melanoma
Gene:
BAX (BCL2-associated X protein), BCL2L1 (BCL2-like 1), CD20 (Membrane Spanning 4-Domains A1), CTNNB1 (Catenin (cadherin-associated protein), beta 1), MT-CO2 (Mitochondrially Encoded Cytochrome C Oxidase II), MTAP (Methylthioadenosine Phosphorylase)
See More ...
Method:
Immunohistochemistry (IHC)